Annual General Meeting 2018 in ChromoGenics AB (publ)

  • 2018-05-16
  • Press release
Annual Report and Results
The Annual General Meeting adopted the profit and loss statement and the balance sheet for the financial year 2017 and decided, in accordance with the Board's proposal, to carry forward SEK 2,551,593 in new account. It was further resolved that no dividend was to be paid.

The Annual General Meeting discharged the Board members and the Managing Director from liability for the financial year 2017. 

Board and auditor's fees
It was resolved to pay to each board member who is not i) employed by the company, ii) founder or main owner of the company, or iii) appointed by or a connected person to founder or main owner of the company, with SEK 100,000 for ordinary board members, and SEK 150,000 for the chairman. It was decided that remuneration to the auditor should be paid on an open account basis.

Election of Board and Auditor
As part of strengthening the company's expertise, Christer Simrén was elected new director of the Board. Anders Brännström, Claes-Göran Granqvist, Mari Broman and Peter Gustafson were re-elected as directors.

Decision on election committee
The Annual General Meeting resolved that the Company, in advance of the next general meeting to be held in 2019, shall establish a nomination committee to propose directors of the board, board- and auditor’s fees etc. The chairman will instruct the three shareholders with the largest holdings of shares/votes in the Company to appoint a representative each that together with the chairman shall constitute the nomination committee.

Share issue authorization
The Annual General Meeting resolved to authorize the Board, on one or more occasions until the next annual general meeting, to issue shares, warrants and / or convertibles. with or without deviation from the shareholders' pre-emption rights and/or an issue in kind, an issue by way of set-off or any other conditions. The authorization can be used to issue maximum 4 218 899 shares, which corresponds to approximately 10 per cent of the outstanding number of shares.

ChromoGenics AB (publ)
Uppsala, May 16, 2018
The Board

Jerker Lundgren, CEO
Susanne Andersson, CFO & Head of Communications
Tel: +46 18 430 0430
Certified Adviser: G&W Fondkommission

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

About ChromoGenics
ChromoGenics offers dynamic glass with controllable heat- and light transmission. The company’s unique technology ConverLight® provides sustainable solar control for increased indoor comfort and energy efficiency. ConverLight® also contributes to Green Building certifications. In 2016 the company started commercial sales to real estate projects in Scandinavia.

ChromoGenics is located in Uppsala, Sweden, and the technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser.